• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications are not effective for a lot of patients suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into personalised micro-interventions to improve mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to understand their predictors of feature and reveal distinct features that deterministically change mood as time passes.

Predictors of Mood

Depression is a major cause of mental illness around the world.1 Yet, only half of those suffering from the condition receive treatment. To improve outcomes, doctors must be able to recognize and treat patients with the highest chance of responding to particular treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from certain treatments. They make use of sensors on mobile phones and a voice assistant incorporating artificial intelligence as well as other digital tools. Two grants were awarded that total over $10 million, they will employ these tools to identify biological and behavioral predictors of the response to antidepressant medication and psychotherapy.

The majority of research to so far has focused on clinical and sociodemographic characteristics. These include demographic variables such as age, sex and education, clinical characteristics such as symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these variables can be predicted from the information available in medical records, only a few studies have utilized longitudinal data to determine the factors that influence mood in people. Many studies do not take into consideration the fact that mood can be very different between individuals. It is therefore important to develop methods that allow for the analysis and measurement of individual differences between mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behaviour and emotions that are unique to each person.

The team also devised a machine-learning algorithm that can create dynamic predictors for each person's mood for depression. The algorithm combines the individual differences to create a unique "digital genotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. The correlation was not strong however (Pearson r = 0,08, BH adjusted P-value 3.55 10 03) and varied widely among individuals.

Predictors of symptoms

Depression is a leading reason for disability across the world1, however, it is often misdiagnosed and untreated2. Depression disorders are usually not treated because of the stigma attached meds to treat depression them and the lack of effective treatments.

To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. However, the current methods for predicting symptoms depend on the clinical interview which has poor reliability and only detects a small variety of characteristics that are associated with inpatient depression treatment centers.2

Machine learning can enhance the accuracy of the diagnosis and treatment of depression by combining continuous digital behavioral phenotypes collected from smartphone sensors with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can be used to provide a wide range of unique behaviors and activities that are difficult to document through interviews, and also allow for continuous, high-resolution measurements.

The study comprised University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were sent online for support or clinical care based on the severity of their postpartum depression treatment near me [resources]. Those with a score on the CAT-DI scale of 35 or 65 were assigned online support via an online peer coach, whereas those who scored 75 patients were referred for psychotherapy in-person.

Participants were asked a series questions at the beginning of the study regarding their psychosocial and demographic characteristics as well as their socioeconomic status. These included age, sex and education, as well as work and financial status; whether they were divorced, partnered or single; their current suicidal thoughts, intentions or attempts; as well as the frequency at that they consumed alcohol. Participants also scored their level of depression severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted each week for those that received online support, and weekly for those receiving in-person treatment.

Predictors of Treatment Response

Research is focusing on personalized treatment for depression. Many studies are aimed at finding predictors that can help doctors determine the most effective drugs to treat each individual. Particularly, pharmacogenetics is able to identify genetic variations that affect how the body metabolizes antidepressants. This lets doctors choose the medications that are likely to be the most effective for each patient, while minimizing the time and effort needed for trial-and error treatments and eliminating any adverse effects.

Another promising approach is to develop predictive models that incorporate the clinical data with neural imaging data. These models can be used to identify which variables are most predictive of a specific outcome, such as whether a drug will improve symptoms or mood. These models can be used to determine the patient's response to a treatment, allowing doctors to maximize the effectiveness.

A new generation of studies uses machine learning methods like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and improve the accuracy of predictive. These models have been shown to be useful in predicting the outcome of treatment for example, the response to antidepressants. These models are getting more popular in psychiatry and it is likely that they will become the standard for future clinical practice.

Research into depression's underlying mechanisms continues, as do ML-based predictive models. Recent findings suggest that the disorder is connected with dysfunctions in specific neural circuits. This suggests that individual depression treatment will be focused on therapies that target these circuits to restore normal functioning.

One method of doing this is through internet-delivered interventions which can offer an individualized and tailored experience for patients. One study found that a program on the internet was more effective than standard care in improving symptoms and providing a better quality of life for people suffering from MDD. A controlled, randomized study of a customized treatment for depression showed that a significant number of patients experienced sustained improvement and had fewer adverse effects.

Predictors of adverse effects

A major challenge in personalized depression treatment is predicting which antidepressant medications will cause very little or no side effects. Many patients have a trial-and error approach, with a variety of medications prescribed before finding one that is effective and tolerable. Pharmacogenetics offers a fresh and exciting method to choose antidepressant medicines that are more efficient and targeted.

There are a variety of variables that can be used to determine the antidepressant to be prescribed, including genetic variations, patient phenotypes such as gender or ethnicity, and comorbidities. However, identifying the most reliable and reliable predictive factors for a specific treatment is likely to require randomized controlled trials with considerably larger samples than those that are typically part of clinical trials. This is because the detection of interaction effects or moderators may be much more difficult in trials that focus on a single instance of treatment per person, rather than multiple episodes of treatment over time.

Furthermore the prediction of a patient's response to a particular medication will also likely need to incorporate information regarding comorbidities and symptom profiles, and the patient's prior subjective experience with tolerability and efficacy. There are currently only a few easily identifiable sociodemographic variables and clinical variables appear to be reliably related to response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to treatment for depression is in its early stages, and many challenges remain. first line treatment for depression, it is important to be able to comprehend and understand the definition of the genetic factors that cause depression, and an accurate definition of an accurate indicator of the response to treatment. Additionally, ethical issues like privacy and the responsible use of personal genetic information must be carefully considered. The use of pharmacogenetics may eventually reduce stigma associated with mental health treatments and improve the outcomes of treatment. But, like any other psychiatric treatment, careful consideration and application is essential. For now, the best course of action is to provide patients with various effective depression medication options and encourage them to speak with their physicians about their experiences and concerns.